Largest ever biobank backed by international peer review

The biggest ever biobank has been given the go-ahead by an international panel of experts to begin recruiting 500,000 people in the UK to provide medical data and material.

The green light follows a three-month pilot phase in the Manchester area of England involving 3,800 participants. This initial phase impressed both the funders and the peer reviewers.

"UK Biobank has the potential, in ways that are not currently available elsewhere, to support a wide range of research, particularly investigations into complex interactions of various exposures, including genetic and lifestyle factors in the pathways to disease and health," reads the panel's report on the initiative.

The unique opportunity to build up such a rich set of data justifies the initial establishment costs of GBP 61 million (€89.6 million), the panel agreed. The funding is being provided by the Medical Research Council, the Wellcome Trust, the Department of Health, the Scottish Executive and the North West Regional Development Agency.

Letters can now start going out to men and women aged between 40 and 69, inviting them to attend assessment centres around the UK. Once consent is provided, each participant will be asked to donate a blood and urine sample, have some standard measurements (such as blood pressure) and complete a confidential lifestyle questionnaire. Over the next 20 to 30 years UK Biobank will allow approved researchers to use these resources to study the progression of illnesses such as cancer, heart disease, diabetes and Alzheimer's disease.

Scientists have known for many years that the risk to an individual of developing different diseases can be traced to a complex combination of different factors: lifestyle and environment; personal susceptibility; and luck. Because the Biobank will involve thousands of people with the same disease, it will be able to show more reliably than ever before why some people develop it while others do not. This should help to find new ways to prevent death and disability from many different conditions.

"UK Biobank, already watched with envy by researchers across the world, will provide a remarkable resource, allowing us to answer important questions about health and disease. This study has the opportunity to make a real difference to the health of future generations," said Mark Walport, Director of the Wellcome Trust.

For further information, please visit:
www.ukbiobank.ac.uk

Copyright ©European Communities, 2006
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg – http://cordis.europa.eu.int. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Commission Joins Forces with Venture Cap…

The Commission has launched a Trusted Investors Network bringing together a group of investors ready to co-invest in innovative deep-tech companies in Europe together with the EU. The Union's investment...

Philips and Medtronic Advocacy Partnersh…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke...

Wearable Cameras Allow AI to Detect Medi…

A team of researchers says it has developed the first wearable camera system that, with the help of artificial intelligence (AI), detects potential errors in medication delivery. In a test whose...

New AI Tool Predicts Protein-Protein Int…

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool...

AI for Real-Rime, Patient-Focused Insigh…

A picture may be worth a thousand words, but still... they both have a lot of work to do to catch up to BiomedGPT. Covered recently in the prestigious journal Nature...

New Research Shows Promise and Limitatio…

Published in JAMA Network Open, a collaborative team of researchers from the University of Minnesota Medical School, Stanford University, Beth Israel Deaconess Medical Center and the University of Virginia studied...

G-Cloud 14 Makes it Easier for NHS to Bu…

NHS organisations will be able to save valuable time and resource in the procurement of technologies that can make a significant difference to patient experience, in the latest iteration of...

Start-Ups will Once Again Have a Starrin…

11 - 14 November 2024, Düsseldorf, Germany. The finalists in the 16th Healthcare Innovation World Cup and the 13th MEDICA START-UP COMPETITION have advanced from around 550 candidates based in 62...

Hampshire Emergency Departments Digitise…

Emergency departments in three hospitals across Hampshire Hospitals NHS Foundation Trust have deployed Alcidion's Miya Emergency, digitising paper processes, saving clinical teams time, automating tasks, and providing trust-wide visibility of...

MEDICA HEALTH IT FORUM: Success in Maste…

11 - 14 November 2024, Düsseldorf, Germany. How can innovations help to master the great challenges and demands with which healthcare is confronted across international borders? This central question will be...

A "Chemical ChatGPT" for New M…

Researchers from the University of Bonn have trained an AI process to predict potential active ingredients with special properties. Therefore, they derived a chemical language model - a kind of...

Siemens Healthineers co-leads EU Project…

Siemens Healthineers is joining forces with more than 20 industry and public partners, including seven leading stroke hospitals, to improve stroke management for patients all over Europe. With a total...